Goldman Sachs maintains Neutral on Dian Diagnostics with a 12-month target price of Rmb19

Overview

This report is Goldman Sachs's review of Dian Diagnostics' (300244.SZ) FY25 results. FY25 revenue met expectations, while net profit turned from loss to profit but came in slightly below Goldman Sachs expectations. The report believes the company's diagnostic services revenue has already shown sequential recovery and the ICL business is gradually bottoming out, but post-pandemic margin pressure and accounts receivable risk remain key investor concerns.

Core views

Goldman Sachs maintains a Neutral rating on Dian Diagnostics and a 12-month target price of Rmb19. The core judgment is that, as China's second-largest independent clinical laboratory and an important participant in IVD, the company's fundamentals are recovering from the trough; AI-related businesses are beginning to show signs of scaling, which may bring incremental revenue and structural cost reductions; however, these medium-term growth opportunities are already largely reflected in the current valuation.

Analysis framework

The report analyzes FY25 actual results, adjustments to Goldman Sachs's forecast model, 2026E-2028E revenue and EPS forecasts, SOTP valuation, and the growth and risk factors of the ICL, IVD, and AI diagnostics businesses.

Methodology notes

• Valuation methodSOTP

  sum-of-the-parts valuation

  The 12-month target price of Rmb19 is based on SOTP valuation: the mature ICL and IVD businesses use a 5-year exit P/E, with a 9.5% discount rate and global peer P/E of 20.7x; the AI business uses a two-stage DCF with a 9.5% discount rate and terminal growth rate of 3%.

• Factor frameworkGS Factor Profile

  growth, financial returns, valuation multiples, and composite percentile comparison

  Goldman Sachs's factor profile compares the stock with the market and industry peers across growth, financial returns, valuation multiples, and composite indicators to provide investment context.

• M&A frameworkM&A Rank

  M&A probability rating

  The report lists Dian Diagnostics with an M&A Rank of 3, indicating a low probability of being acquired, and it is typically not included in the target price.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Dian Diagnostics (300244.SZ)

  Covered company and rating target

  Strengths

  China's second-largest ICL company and also an important participant in the IVD industry; net profit has turned from loss to profit, and diagnostic services revenue has recovered sequentially; revenue contribution from tertiary hospitals exceeded 50% for the first time; AI-related business is beginning to scale up.

  Weaknesses

  FY25 revenue still declined 17% YoY; net profit was slightly below Goldman Sachs expectations; post-pandemic margin compression and accounts receivable risk have not yet been fully eliminated.

  Comparison

  Goldman Sachs evaluates it relatively within its China A-share healthcare coverage universe, with the target price based on a combination of global peer P/E and AI business DCF valuation.

  Risks

  Intensifying industry competition, sharp declines in testing item prices, higher-than-expected impairment of accounts receivable, and implementation of IVD volume-based procurement policies.

Key data

• FY25 revenueRmb10,096mnDown 17% YoY, broadly in line with Goldman Sachs expectation of Rmb10,336mn.
• FY25 net profitRmb44mnTurned positive from the FY24 net loss of Rmb357mn, but slightly below Goldman Sachs expectations.
• 12-month target priceRmb19Maintained unchanged, based on SOTP valuation.
• Listed report share priceRmb19.26Closing price as of April 21, 2026.
• 2026E revenue forecastRmb11,327mnCut by 1.8% from the previous forecast of Rmb11,537mn.
• 2027E revenue forecastRmb13,901mnCut by 1.5% from the previous forecast of Rmb14,117mn.
• 2028E revenue forecastRmb16,771mnCut by 1.2% from the previous forecast of Rmb16,977mn.
• 2026E EPSRmb0.62Cut by 1.2% from the previous forecast of Rmb0.63.
• 2027E EPSRmb0.87Broadly flat versus the previous forecast; the report shows an upward revision of 0.8%.
• 2028E EPSRmb1.05Cut by 3.1% from the previous forecast of Rmb1.08.

Impact & implications

The report's investment implication for Dian Diagnostics is neutral: earnings recovery and the scaling of AI business provide fundamental support, but the target price is below the current price, while post-pandemic margins, accounts receivable, and industry policy still weigh on valuation.

Risks

• Intensifying industry competition.
• Sharp declines in testing item prices.
• Higher-than-expected impairment of accounts receivable.
• Implementation of VBP policies in the IVD industry brings price and margin pressure.

What to watch

• The pace of ramp-up for self-developed products.
• New VBP policies in the IVD industry.
• Commercialization progress of AI-enabled diagnostic solutions.
• Whether the recovery in diagnostic services revenue can continue from 2H25 into 2026.
• Whether impairment of accounts receivable comes in below or above expectations.